October 2010

The continuing education article reviews emerging therapies for the treatment of gastrointestinal disorders.

Increased generic substitution is projected to erode prices and outpace class utilization growth for proton pump inhibitors in 2010.

The pharmacy benefits industry can learn ways to streamline processes, make cost-effective changes, and increase efficiency by listening to patients with chronic illness.

At the population level, comparative effectiveness research can inform policies and incentives that result in improvements in health and minimize risk.

Collaboration among payers, distributors, developers, clinicians, consultants, and patients is the way to succeed in managing US healthcare in the future.

We have the opportunity to take what we learned in the 1980s and 1990s and create models of care that make sense for us all.

Proton pump inhibitors are cost-effective options for stress ulcer prophylaxis.

Dose consolidation and quantity limit initiatives decreased utilization and cost outcomes for select mental health drugs in a fee-for-service Medicaid environment.

Clarian Health, an 11-hospital health system, developed and managed a multihospital formulary through focused planning and collaboration.